错配修复蛋白及PD-L1在弥漫浸润型胃癌中的表达及意义  

The expression and significance of mismatch repair protein and PD-L1 in diffuse invasive gastric cancer

作　　者：李薇[1] 王文杰 谷昀昌 虞红珍[3] 程怀东[1] Li Wei;Wang Wen-jie;Gu Yun-chang;Yu Hong-zhen;Cheng Huai-dong(Department of Oncology,The Second Hospital of Anhui Medical University,Hefei 230601,China;The Second Clinic Medical College of Anhui Medical University,Hefei 230000,China;Department of Pathology,The Second Hospital of Anhui Medical University,Hefei 230601,China)

机构地区：[1]安徽医科大学第二附属医院肿瘤科,合肥230601 [2]安徽医科大学第二临床医学院,合肥230000 [3]安徽医科大学第二附属医院病理科,合肥230601

出　　处：《湖南师范大学学报（医学版）》2021年第2期167-169,共3页Journal of Hunan Normal University(Medical Sciences)

摘　　要：目的:研究DNA错配修复(mismatch repair,MMR)蛋白MLHl、PMS2、MSH2、MSH6及程序性死亡配体-1(programmed death ligand 1,PD-L1)在弥漫浸润型胃癌中的表达及意义。方法:选取2017年1月~2019年8月我院收治的弥漫浸润型胃癌33例,收集病理资料,免疫组化方法检测胃癌组织中MLHl、PMS2、MSH2、MSH6及PD-L1的表达。结果:4种DNA错配修复蛋白MLHl、PMS2、MSH2、MSH6在33例弥漫浸润型胃癌组织中检测出MLH1、PMS2缺失各1例,dMMR发生率6.1%;PD-L1未见阳性表达。结论:弥漫浸润型胃癌中DNA错配修复功能缺陷发生率低,提示MSI-H发生率可能不高;肿瘤组织中PD-L1阳性表达率低,提示弥漫浸润型胃癌应用免疫治疗,特别是PD-1/PD-L1免疫检查点抑制剂临床获益的可能性不大。Objective To study the expression and significance of DNA mismatch repair (MMR) proteins MLH1,PMS2,MSH2,MSH6 and programmed death ligand 1(PD-L1) in diffusely invasive gastric cancer.Methods Select 33 cases of diffuse invasive gastric cancer admitted to our hospital from January 2017 to August 2019,collect pathological data,and detect the expression of MLH1,PMS2,MSH2,MSH6 and PD-L1 in gastric cancer tissue by immunohistochemical method.Results Four DNA mismatch repair proteins,MLH1,PMS2,MSH2,and MSH6,were detected in 33 cases of diffusely invasive gastric cancer with 1 case each of MLH1 and PMS2 deletion,with a dMMR incidence of 6.1%;no positive expression of PD-L1.Conclusion The incidence of DNA mismatch repair defects in diffusely invasive gastric cancer is low,indicating that the incidence of MSI-H may not be high;the low positive expression rate of PD-L1 in tumor tissues indicates that immunotherapy should be used for diffusely invasive gastric cancer,especially PD-1/PD-L1 immune checkpoint inhibitors are unlikely to benefit clinically.

关 键 词：错配修复蛋白 程序性死亡配体-1 弥漫浸润型胃癌 

分 类 号：R735.2[医药卫生—肿瘤]